Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Eisai Applies for Pediatric Indication for lecainide Based on Data in Public Domain
January 25, 2010
- Abbott's Everolimus-Eluting Stent XIENCE V Approved in Japan
January 25, 2010
- Anti-Flu Agent Rapiacta Approved: Shionogi
January 25, 2010
- Seikagaku Receives Not-Approvable Letter for Gel-200 from FDA
January 25, 2010
- Flu Vaccines from GSK, Novartis Receive First “Emergency Approval”
January 25, 2010
- Kobayashi Aims at \4.5 Bil. with New Products in FY2010
January 25, 2010
- Sales of Crestor in Japan to Exceed ¥100 Bil.
January 25, 2010
- New Subcommittee to Be Created for Regulatory Reform
January 25, 2010
- GLs for Ads on Illegal Drugs on Internet to Be Revised
January 25, 2010
- Informed Consent Not Obtained from Many Recipients of Albumin Products
January 25, 2010
- NCs to Take Over Part of Long-Term Debt
January 25, 2010
- Gov't New Growth Strategy to Stimulate Market for OTC Drugs: Mr Hatori
January 25, 2010
- Hisamitsu: Sales Up 5% Driven by Mohrus Series
January 25, 2010
- Korosho to Present Bill to Amend Preventive Vaccination Law
January 25, 2010
- Merck Serono to Increase Market Share for Gonalef, Saizen
January 25, 2010
- Blopress Remains No. 1 for 6 Terms in a Row: Domestic Drugs Sales Ranking
January 25, 2010
- No Serious Concern about Safety of New-Type Flu Vaccines Made in Japan
January 25, 2010
- 26 Listed JPMA Member Companies' Combined Operating Profits Up 28.8% in 1st Half of FY2009
January 25, 2010
- Actemra Approved in the US: Chugai, Roche
January 25, 2010
- Bayer to Transfer Shinbit to Hospira
January 25, 2010
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…